US health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
The Food and Drug Administration said yesterday it approved the pill Sovaldi in combination with older drugs to treat the main forms of hepatitis C that affect US patients.
Current treatments for hepatitis C can take up to a year of therapy and involve weekly injections of a drug that causes flu-like side effects. That approach only cures about three out of four patients.
Sovaldi is a daily pill that in clinical trials cured roughly 90 per cent of patients in just 12 weeks, when combined with the older drug cocktail.
Between 3 million and 4 million Americans are estimated to carry the blood-borne virus, though most do not even know they are infected. Others have tested positive but are waiting for more effective treatments to become available.
Hepatitis C symptoms may not appear until two or three decades after infection, though the virus can cause liver failure, cirrhosis and cancer if left untreated.
Dr. Donald Jensen of the University of Chicago said he's optimistic that new drugs like Sovaldi will increase treatment of the disease, which is blamed for 15,000 US deaths per year.
"I'm hoping that these new, less toxic therapies will drive more people to get tested and more primary care physicians to test their patients, knowing that the therapy is going to be more effective and easier," said Jensen, who directs the university's center for liver diseases.
Gilead Sciences Inc., based in Foster City, California, is one of a half-dozen companies battling over the market more effective treatments for hepatitis C. Many industry analysts expect Sovaldi to quickly dominate the field with sales of over USD 1.6 billion next year.
Gilead said yesterday it would price the drug at USD 84,000 for one 12-week supply. Patients with a less common subtype of the disease may need to take the drug for 24 weeks, raising the cost to USD 168,000 for one course of treatment.
Drugs already on the market run between USD 25,000 and USD 50,000 for a course of treatment.
The approval comes as the US government urges all baby boomers to get tested for the disease.
People born between 1945 and 1965 are five times more likely than other age groups to have hepatitis C, with many having contracted the virus by sharing needles or having sex with an infected person in their youth.
For most of the last 20 years, the standard treatment for hepatitis C involved a gruelling one-year regimen of pills and injections that caused nausea, fever and headaches and cured fewer than half of patients.
